MENLO PARK, California,
Oct. 27, 2020 /PRNewswire/
-- Drawbridge Health, a healthcare technology company
redefining the blood draw experience for both patients and
healthcare providers, today announced a further investment from
Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon Pharma")
as well as a new research and development collaboration
agreement. Drawbridge Health also reported that it has
secured a strategic investment from new investor TOHO HOLDINGS CO.,
LTD. ("TOHO HOLDINGS"), in addition to a follow-on investment from
Kyoto University Innovation Capital
("KYOTO-iCAP"). The investments will fuel Drawbridge Health's
expansion in the Japanese market and support adoption of the
company's innovative blood collection technology, the OneDraw™
Blood Collection Device.
The collaboration between Drawbridge Health and Sumitomo
Dainippon Pharma will focus initially on the development of a
biomarker panel for lifestyle-related diseases such as diabetes and
diabetic complications. "Our research and development collaboration
with Drawbridge Health has been undertaken to address the
significant concern in Japan
around lifestyle-related diseases by embracing OneDraw as a novel,
transformative innovation" said Hiroyuki
Baba, Senior Executive Officer at Sumitomo Dainippon
Pharma.
Professor Nobuya Inagaki, M.D.,
Ph.D., Chairman of the Department of Diabetes, Endocrinology and
Nutrition at Kyoto University further
highlighted the significance of the collaboration between
Drawbridge Health and Sumitomo Dainippon Pharma. "This
collaboration is forward-thinking, as it will help advance
much-needed initiatives, resources and support the expansion of
telemedicine in the Japanese medical field, particularly for
lifestyle-related diseases."
"There is tremendous potential for changing the trajectory of
diabetes and lifestyle disease in Japan with the OneDraw device. We are excited
to partner with Drawbridge Health to improve
the health of millions," said Mr. Atsushi
Udoh, President and Representative Director,
TOHO HOLDINGS.
"Globally, 2020 has proven that healthcare systems must quickly
adapt to unexpected and ongoing challenges. Access to health
information is more important than ever, and we appreciate the
commitments from Sumitomo Dainippon Pharma and TOHO HOLDINGS as we
continue our growth and vision in Japan. We also continue to be extremely
grateful for the ongoing collaboration and relationship with
Kyoto University and KYOTO-iCAP," said
Lee McCracken, CEO of Drawbridge Health.
Drawbridge Health is committed to improving healthcare globally
through more accessible blood sampling, beginning with the 2019
FDA-cleared and 2020 CE-marked OneDraw A1C Test System. OneDraw is
a small, single use device that draws, collects, and stabilizes a
capillary blood sample from the upper arm. This novel device is
easy to use and enables blood to be drawn comfortably and
conveniently without the need to visit a lab.
About Drawbridge Health
Founded in 2015 by GE Ventures
and GE Healthcare, Drawbridge Health is a healthcare technology
company focused on reinventing the blood draw experience, enabling
comfortable convenient blood sample collection anytime and
anywhere. By integrating engineering, chemistries, and modular
design, Drawbridge Health has developed a people-friendly system
for collecting and stabilizing blood samples, opening new doors to
enable access to important health information. For more
information, please visit www.drawbridgehealth.com.
Contact:
Eddy
Garcia
egarcia@dbhealth.com
Learn more about the investors:
Sumitomo Dainippon Pharma
TOHO HOLDINGS CO., LTD.
KYOTO-iCAP
Photo -
https://mma.prnewswire.com/media/1318588/dbh_onedraw_kit_04.jpg
Logo
- https://mma.prnewswire.com/media/899446/Drawbridge_Logo.jpg